ReviewCancer gene therapy2006
Gene therapy with drug resistance genes.
Review in Cancer gene therapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Advances in HIV Gene Therapy.International journal of molecular sciences · 2024Review
- Inhibition of c-MYC-miRNA 19 Pathway Sensitized CML K562 Cells to Etoposide via NHE1 Upregulation.Oxidative medicine and cellular longevity · 2022Article
- Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance.Frontiers in oncology · 2020Review
- Creation of zebularine-resistant human cytidine deaminase mutants to enhance the chemoprotection of hematopoietic stem cells.Protein engineering, design & selection : PEDS · 2016Article
- Metabolomics guides rational development of a simplified cell culture medium for drug screening against Trypanosoma brucei.Antimicrobial agents and chemotherapy · 2013Article
- Combined preconditioning and in vivo chemoselection with 6-thioguanine alone achieves highly efficient reconstitution of normal hematopoiesis with HPRT-deficient bone marrow.Experimental hematology · 2012Article
- Imaging stem cell-derived persistent foci after in vivo selection of lentiviral MGMT-P140K transduced murine bone marrow cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Development of gene therapy in association with clinically used cytotoxic deoxynucleoside analogues.Cancer gene therapy · 2009Review
- Interactions of human O(6)-alkylguanine-DNA alkyltransferase (AGT) with short double-stranded DNAs.Biochemistry · 2008Article
- Interfering RNA-mediated purine analog resistance for in vitro and in vivo cell selection.Blood · 2008Article
- Potential of tumour cells for delivering oncolytic viruses.Gene therapy · 2008Review
- Gene-modified bone marrow cell therapy for prostate cancer.Gene therapy · 2008Review
- Gene therapy in head and neck cancer: a review.Postgraduate medical journal · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A major side effect of cancer chemotherapy is myelosuppression. Expression of drug-resistance genes in hematopoietic stem cells (HSC) using gene transfer methodologies holds the promise of overcoming marrow toxicity in cancer chemotherapy. Adequate protection of marrow cells in cancer patients from myelotoxicity in this way would permit the use of escalating doses of chemotherapy for eradicating residual disease. A second use of drug-resistance genes is for coexpression with a therapeutic gene in HSCs to provide a selection advantage to gene-modified cells. In this review, we discuss several drug resistance genes, which are well suited for in vivo selection as well as other newer candidate genes with potential for use in this manner.
Indexed as
Identifiers
16211086What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.